Author:
van Hellemond Irene E. G.,Geurts Sandra M. E.,Tjan-Heijnen Vivianne C. G.
Funder
Maastricht University Medical Center
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Oncology
Reference57 articles.
1. Burstein HJ, Temin S, Anderson H, Buchholz TA, Davidson NE, Gelmon KE, et al. Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: american society of clinical oncology clinical practice guideline focused update. J Clin Oncol. 2014;32(21):2255–69.
2. •• Early Breast Cancer Trialists’ Collaborative G, Dowsett M, Forbes JF, Bradley R, Ingle J, Aihara T, et al. Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials. Lancet. 2015;386(10001):1341–52. Important patient-level meta-analysis comparing several strategies of 5-year adjuvant endocrine therapy.
3. •Tjan-Heijnen VCG, van Hellemond IEG, Peer PGM, Swinkels ACP, Smorenburg CH, van der Sangen MJC, Kroep JR, De Graaf H, Honkoop AH, Erdkamp FLG, van den Berkmortel F, de Boer M, de Roos WK, Linn SC, Imholz ALT, Seynaeve CM, Dutch Breast Cancer Research Group for the DI (2017) Extended adjuvant aromatase inhibition after sequential endocrine therapy (DATA): a randomised, phase 3 trial. Lancet Oncol 18 (11):1502-1511. Trial on extended adjuvant aromatase inhibitor therapy.
4. • Blok EJ, Kroep JR, Meershoek-Klein Kranenbarg E, Duijm-de Carpentier M, Putter H, van den Bosch J, Maartense E, van Leeuwen-Stok AE, Liefers GJ, Nortier JWR, Rutgers EJT, van de Velde CJH, Group IS (2018) Optimal Duration of Extended Adjuvant Endocrine Therapy for Early Breast Cancer; Results of the IDEAL Trial (BOOG 2006-05). J Natl Cancer Inst 110 (1). Trial on extended adjuvant aromatase inhibitor therapy.
5. • Mamounas EP, Bandos H, Lembersky BC, Geyer JCE, Fehrenbacher L, Graham ML, Chia SL, Brufsky AM, Hennessy BT, Soori GS, Dakil SR, Seay TE, Wade IJL, McCarron EC, Paik S, Swain SM, Wickerham DL, Wolmark N A Randomized, double-blinded, placebo-controlled clinical trial of extended adjuvant endocrine therapy (tx) with letrozole (L) in postmenopausal women with hormone-receptor (+) breast cancer (BC) who have completed previous adjuvant tx with an aromatase inhibitor (AI): results from NRG Oncology/NSABP B-42. In: Presented at: 2016 San Antonio Breast Cancer Symposium; December 6–10; San Antonio, TX, 2016. Trial on extended adjuvant aromatase inhibitor therapy.
Cited by
45 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献